全文获取类型
收费全文 | 220870篇 |
免费 | 19345篇 |
国内免费 | 12085篇 |
专业分类
耳鼻咽喉 | 2235篇 |
儿科学 | 3278篇 |
妇产科学 | 4824篇 |
基础医学 | 24427篇 |
口腔科学 | 4430篇 |
临床医学 | 28487篇 |
内科学 | 34274篇 |
皮肤病学 | 2375篇 |
神经病学 | 11436篇 |
特种医学 | 7377篇 |
外国民族医学 | 79篇 |
外科学 | 23068篇 |
综合类 | 33138篇 |
现状与发展 | 42篇 |
一般理论 | 38篇 |
预防医学 | 14670篇 |
眼科学 | 6038篇 |
药学 | 23046篇 |
166篇 | |
中国医学 | 11000篇 |
肿瘤学 | 17872篇 |
出版年
2024年 | 518篇 |
2023年 | 2690篇 |
2022年 | 7147篇 |
2021年 | 9712篇 |
2020年 | 7082篇 |
2019年 | 6450篇 |
2018年 | 6998篇 |
2017年 | 6278篇 |
2016年 | 5791篇 |
2015年 | 9058篇 |
2014年 | 11632篇 |
2013年 | 11303篇 |
2012年 | 16682篇 |
2011年 | 18189篇 |
2010年 | 11874篇 |
2009年 | 9527篇 |
2008年 | 12437篇 |
2007年 | 12586篇 |
2006年 | 12088篇 |
2005年 | 11803篇 |
2004年 | 8252篇 |
2003年 | 7443篇 |
2002年 | 6361篇 |
2001年 | 5305篇 |
2000年 | 5273篇 |
1999年 | 5138篇 |
1998年 | 2801篇 |
1997年 | 2619篇 |
1996年 | 2229篇 |
1995年 | 2062篇 |
1994年 | 1828篇 |
1993年 | 1110篇 |
1992年 | 1850篇 |
1991年 | 1566篇 |
1990年 | 1320篇 |
1989年 | 1137篇 |
1988年 | 1090篇 |
1987年 | 930篇 |
1986年 | 766篇 |
1985年 | 609篇 |
1984年 | 384篇 |
1983年 | 321篇 |
1982年 | 176篇 |
1981年 | 189篇 |
1980年 | 148篇 |
1979年 | 252篇 |
1978年 | 165篇 |
1977年 | 139篇 |
1974年 | 139篇 |
1972年 | 123篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
53.
54.
55.
56.
T.-Y. Huang Y.-J. Hsia M.-Y. Sung Y.-T. Wu P.-C. Hsu 《International journal of oral and maxillofacial surgery》2021,50(8):1100-1106
Zygomatic implant treatment is widely applied for severe maxillary atrophy to help rehabilitate the maxillary dentition. This retrospective study was performed to evaluate the actual radiographic bone–implant contact (rBIC) lengths of zygomatic implants. The records of 28 patients who underwent zygomatic implant surgery and subsequent follow-up examinations between August 2013 and September 2018 in the Department of Oral and Maxillofacial Surgery, Taipei Tzu Chi Hospital were reviewed. The surgeries were performed by a single surgeon using the same treatment protocol. All patients had a computed tomography scan at 1 year after the surgery. Using three-dimensional imaging software, an investigator measured the rBIC lengths of 66 implants and documented their clinical status. The implant survival rate was 100%. The mean rBIC length was significantly longer in male patients than in female patients (20.80 ± 5.88 mm versus 17.79 ± 6.34 mm; P = 0.028). The mean rBIC length of double zygomatic implants was significantly longer when compared to that of single implants (21.11 ± 6.23 mm versus 17.75 ± 5.85 mm; P = 0.027). This article is novel in reporting the exact rBIC lengths of zygomatic implants in a clinical setting. The results showed that zygomatic implants are a viable treatment modality for full-mouth rehabilitation. 相似文献
57.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
58.
我国奶牛养殖规模不断扩大,奶业产值比重逐步提高,给奶牛疫病防治带来巨大压力。奶牛乳房炎及细菌性肺炎等呼吸系统疾病和细菌性肠炎等消化系统疾病最为常见,抗菌药物的使用成为主要防治手段。但抗菌药物的不当使用易使细菌产生耐药性,增加临床治疗的成本和难度,危害我国奶牛产业发展。本文对截至2021年7月我国和美国、英国、日本、欧盟批准用于奶牛的抗菌药物产品进行整理、统计与分析,包括抗菌药物的分类、剂型以及适应证等,旨在为我国奶牛用抗菌药物管理、合理用药和新兽药开发提供参考。 相似文献
59.
60.